{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:01:37Z","timestamp":1793736097999,"version":"4.6.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014101","name":"Novavax Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020768","name":"University of Utah Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020768","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007747","name":"University of Utah","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007747","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.vaccine.2026.128954","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:01:41Z","timestamp":1784689301000},"page":"128954","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Real-world effectiveness and safety of protein-based and mRNA COVID-19 vaccines (BEEHIVE trial)"],"prefix":"10.1016","volume":"88","author":[{"given":"Sarang K.","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steph","family":"Battan-Wraith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Thiese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Rowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German L.","family":"Ellsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca V.","family":"Fink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiyun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah W.","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Toback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Dunkle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Rousculp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vaccine.2026.128954_bb0005","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.9135","article-title":"Safety, immunogenicity, and efficacy of the NVX-CoV2373 COVID-19 vaccine in adolescents: a randomized clinical trial","volume":"6","author":"Anez","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128954_bb0010","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2116185","article-title":"Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico","volume":"386","author":"Dunkle","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128954_bb0015","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S1473-3099(22)00420-0","article-title":"Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial","volume":"22","author":"Mallory","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128954_bb0020","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S1473-3099(22)00271-7","volume":"22","author":"Munro","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"22","key":"10.1016\/j.vaccine.2026.128954_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126165","article-title":"A Brighton collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine","volume":"42","author":"Pather","year":"2024","journal-title":"Vaccine"},{"issue":"45","key":"10.1016\/j.vaccine.2026.128954_bb0030","doi-asserted-by":"crossref","first-page":"6762","DOI":"10.1016\/j.vaccine.2023.07.040","article-title":"A Brighton collaboration standardized template with key considerations for a benefit\/risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373), a recombinant spike protein vaccine with matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses","volume":"41","author":"Wilkinson","year":"2023","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.vaccine.2026.128954_bb0035","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 Covid-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128954_bb0040","article-title":"The platform trial in COVID-19 priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old","volume":"89","author":"McLeod","year":"2024","journal-title":"J Infect"},{"issue":"10318","key":"10.1016\/j.vaccine.2026.128954_bb0045","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128954_bb0050","doi-asserted-by":"crossref","first-page":"e496","DOI":"10.1093\/infdis\/jiad519","article-title":"The Novavax heterologous coronavirus disease 2019 booster demonstrates lower reactogenicity than messenger RNA: a targeted review","volume":"230","author":"Marchese","year":"2024","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128954_bb0055","article-title":"Reactogenicity differences between adjuvanted, protein-based and messenger ribonucleic acid (mRNA)-based COVID-19 vaccines","volume":"12","author":"Rousculp","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128954_bb0060","article-title":"Burden and impact of reactogenicity among adults receiving COVID-19 vaccines in the United States and Canada: results from a prospective observational study","volume":"12","author":"Rousculp","year":"2024","journal-title":"Vaccines (Basel)."},{"issue":"3","key":"10.1016\/j.vaccine.2026.128954_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2025.106447","article-title":"The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose","volume":"90","author":"Mazarakis","year":"2025","journal-title":"J Infect"},{"issue":"Supplement_1","key":"10.1016\/j.vaccine.2026.128954_bb0070","volume":"13","author":"Yoon","year":"2026","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128954_bb0075","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1080\/14760584.2022.2098719","article-title":"Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis","volume":"21","author":"Sutton","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128954_bb0080","series-title":"Post-COVID-19 Vaccine Health Status Survey","author":"FY2022 Ministry of Health, Labour and Welfare Commissioned Project","year":"2022"},{"issue":"10318","key":"10.1016\/j.vaccine.2026.128954_bb0085","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2026.128954_bb0090","doi-asserted-by":"crossref","DOI":"10.2196\/57242","article-title":"COVID-19 vaccine preferences in general populations in Canada, Germany, the United Kingdom, and the United States: discrete choice experiment","volume":"10","author":"Salisbury","year":"2024","journal-title":"JMIR Public Health Surveill"},{"key":"10.1016\/j.vaccine.2026.128954_bb0095","author":"US Food and Drug Administration"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128954_bb0100","doi-asserted-by":"crossref","first-page":"180","DOI":"10.15585\/mmwr.mm7308a5","volume":"73","author":"DeCuir","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128954_bb0105","doi-asserted-by":"crossref","first-page":"77","DOI":"10.15585\/mmwr.mm7304a2","volume":"73","author":"Link-Gelles","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2026.128954_bb0110","doi-asserted-by":"crossref","DOI":"10.2196\/80858","article-title":"Real-world effectiveness and non-inferiority evaluation and comparison of mRNA- and protein-based COVID-19 vaccines: a randomized study protocol (BEEHIVE)","volume":"15","author":"Yoon","year":"2026","journal-title":"JMIR Res Protoc"},{"key":"10.1016\/j.vaccine.2026.128954_bb0115","author":"Novavax"},{"key":"10.1016\/j.vaccine.2026.128954_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127496","article-title":"Real-world effectiveness of NVX-CoV2373 and BNT162b2 mRNA COVID-19 vaccination in South Korea","volume":"62","author":"Gwak","year":"2025","journal-title":"Vaccine"},{"issue":"Pt 1","key":"10.1016\/j.vaccine.2026.128954_bb0125","article-title":"Relative effectiveness of homologous NVX-CoV2373 and BNT162b2 COVID-19 vaccinations in South Korea","volume":"43","author":"Gwak","year":"2025","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128954_bb0130","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1111\/bcp.13280","article-title":"Defining the noninferiority margin and analysing noninferiority: an overview","volume":"83","author":"Althunian","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.vaccine.2026.128954_bb0135","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jclinepi.2023.09.014","article-title":"The use of the E-value for sensitivity analysis","volume":"163","author":"Chung","year":"2023","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128954_bb0140","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2026.128954_bb0145","author":"Nextstrain"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128954_bb0150","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiaf007","article-title":"Effectiveness of mRNA COVID-19 vaccines and hybrid immunity in preventing SARS-CoV-2 infection and symptomatic COVID-19 among adults in the United States","volume":"231","author":"Feldstein","year":"2025","journal-title":"J Infect Dis"},{"issue":"24","key":"10.1016\/j.vaccine.2026.128954_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126288","article-title":"Disparities in COVID-19 vaccination receipt by race, ethnicity, and social determinants of health among a large patient population in a network of community-based healthcare centers","volume":"42","author":"Groom","year":"2024","journal-title":"Vaccine"},{"issue":"28","key":"10.1016\/j.vaccine.2026.128954_bb0160","doi-asserted-by":"crossref","first-page":"985","DOI":"10.15585\/mmwr.mm7028a1","article-title":"COVID-19 vaccination coverage among insured persons aged \u226516 years, by race\/ethnicity and other selected characteristics - eight integrated health care organizations, United States, December 14, 2020-May 15, 2021","volume":"70","author":"Pingali","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128954_bb0165","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s13690-025-01740-y","article-title":"Racial and ethnic disparities in COVID-19 vaccination: a systematic review and meta-analysis","volume":"83","author":"Iezadi","year":"2025","journal-title":"Arch Public Health"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128954_bb0170","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s00330-020-07160-6","article-title":"Diagnostic accuracy and safety of percutaneous MRI-guided biopsy of solid renal masses: single-center results after 4.5 years","volume":"31","author":"Cazzato","year":"2021","journal-title":"Eur Radiol"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128954_bb0175","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.cmi.2021.07.039","article-title":"Self-testing for the detection of SARS-CoV-2 infection with rapid antigen tests for people with suspected COVID-19 in the community","volume":"28","author":"Stohr","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128954_bb0180","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae304","article-title":"Performance of and severe acute respiratory syndrome coronavirus 2 diagnostics based on symptom inset and close contact exposure: an analysis from the test us at home prospective cohort study","volume":"11","author":"Herbert","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128954_bb0185","doi-asserted-by":"crossref","first-page":"975","DOI":"10.7326\/M23-0385","article-title":"Performance of rapid antigen tests to detect symptomatic and asymptomatic SARS-CoV-2 infection\u202f: a prospective cohort study","volume":"176","author":"Soni","year":"2023","journal-title":"Ann Intern Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26007632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26007632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:41:10Z","timestamp":1789504870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26007632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":37,"alternative-id":["S0264410X26007632"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128954","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness and safety of protein-based and mRNA COVID-19 vaccines (BEEHIVE trial)","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128954","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128954"}}